scholarly journals Risk of Hyperkalemia Caused by Nafamostat Mesilate in Geriatric Patients

2020 ◽  
Vol 46 (10) ◽  
pp. 561-566
Author(s):  
Hiroki Arihara ◽  
Hiroki Mase ◽  
Takashi Kagaya ◽  
Fumihiro Mizokami ◽  
Teppei Akiyama
Keyword(s):  
Geriatric Patients ◽  
Nafamostat Mesilate

Aging and Autism

2012 ◽  
Vol 17 (2) ◽  
pp. 69-75 ◽  
Author(s):  
Pamela A. Smith
Keyword(s):  
Health Care ◽  
Autism Spectrum Disorders ◽  
Patient Group ◽  
Older Patients ◽  
Geriatric Patients ◽  
Recent Literature ◽  
Communication Disorders ◽  
Autism Spectrum ◽  
Need For Support ◽  
Spectrum Disorders

In this article, I will review the available recent literature about the aging population with autism, a patient group that researchers know little about and a group that is experiencing a growing need for support from communication disorders professionals. Speech-language pathologists working with geriatric patients should become familiar with this issue, as the numbers of older patients with autism spectrum disorders is likely to increase. Our profession and our health care system must prepare to meet the challenge these patients and residents will present as they age.

Responding to Clinicians' Challenges in Working With Geriatric Patients

2011 ◽  
Vol 16 (1) ◽  
pp. 22-29
Author(s):  
Lisa Y. Milliken ◽  
Dawn Ralph ◽  
Sally Jones-McNamara
Keyword(s):  
Health Care ◽  
Geriatric Patients ◽  
Clinical Scenario ◽  
Medical Diagnoses ◽  
Communication Deficits ◽  
Resident Care ◽  
Physical Limitations

Clinicians work with older residents who have not only multiple physical limitations, but cognitive loss, communication deficits, dysphagia, and multiple medical diagnoses. They must work within procedural, regulatory, and reimbursement systems that challenge them to provide optimal resident care. In this article, the authors will discuss some specific challenges brought forth by clinicians in response to a clinical scenario and will provide information and feedback from several health-care consultants.

Aortic Valve Replacement in Geriatric Patients: Are Sutureless Valves the Way to go?

2016 ◽  
Vol 64 (S 01) ◽  
Author(s):  
J. Umminger ◽  
M. Arar ◽  
K. Höffler ◽  
A. Martens ◽  
C. Bara ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Geriatric Patients ◽  
The Way

The Anticoagulant and Hemorrhagic Effects of DHG, a New Depolymerized Holothurian Glycosaminoglycan, on Experimental Hemodialysis in Dogs

1997 ◽  
Vol 77 (06) ◽  
pp. 1148-1153 ◽  
Author(s):  
Kazuhisa G Minamiguchi ◽  
Keiko T Kitazato ◽  
Eiji Sasaki ◽  
Hideki Nagase ◽  
Kenji Kitazato
Keyword(s):  
Low Molecular Weight Heparin ◽  
Bleeding Time ◽  
Activated Partial Thromboplastin Time ◽  
Low Molecular Weight ◽  
Nafamostat Mesilate ◽  
Extracorporeal Circuit ◽  
Clotting Time ◽  
Prolonged Bleeding Time ◽  
Hemorrhagic Risk ◽  
Effective Doses

SummaryWe studied the use of depolymerized holothurian glycosaminoglycan (DHG) as an anticoagulant in experimental beagle-dog hemodialysis using a hollow-fiber dialyzer compared to that using unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and nafamostat mesilate (FUT). Effectiveness was based on 5 h hemodialysis and no marked clot deposition in the extracorporeal circuit. At effective doses, UFH and LMWH significantly prolonged template bleeding time, in sharp contrast to FUT and DHG, which scarcely prolonged bleeding time during hemodialysis. DHG prolonged activated partial thromboplastin time (APTT) about 6 times that of normal plasma and prolonged thrombin clotting time (TCT) markedly; FUT showed marked APTT prolongation but hardly prolonged TCT in the hemodialysis circuit at the effective dose. The anticoagulant profile of DHG thus differs completely from that of FUT. These results suggest that DHG may be useful as anticoagulant for hemodialysis with low hemorrhagic risk.

Sign in / Sign up

Export Citation Format

Share Document